Key Highlights

  • Shares closed down 16.27% at USD 11.01 on November 3, 2026, from USD 13.15 on November 2.
  • Third quarter 2026 net sales were USD 142.4 million, up 2.7% from a year earlier.
  • 2026 net sales guidance is now USD 590 million to USD 595 million, below the earlier USD 600 million to USD 610 million.
  • Net income attributable to the company was USD 6.0 million, against USD 3.2 million a year earlier.
  • Total Debt fell to about USD 229.8 million from about USD 294.0 million at the end of 2025 (calculated).

What Moved Bioventus Shares Today (down USD 2.14, 16.27%)

Bioventus (NASDAQ:BVS) was down 16.27% to USD 11.01 in regular trading on November 3, 2026, compared with USD 13.15 on Monday, November 2. Volume was about 574.72K shares per the screen.

The likely trigger is the guidance change. In a company press release dated November 2, 2026, the company lowered its 2026 net sales range even as quarterly profit improved. Modest growth and a lower Revenue outlook often weigh more on a stock than an Earnings improvement.

The Quarter and the Guidance Reset

Net sales for the quarter ended September 26, 2026 were USD 142.4 million, up 2.7% from USD 138.7 million, or 2.9% in constant currency. The new full-year range of USD 590 million to USD 595 million replaces USD 600 million to USD 610 million and implies growth of roughly 4% to 5%.

Net income was USD 6.9 million, of which USD 6.0 million was attributable to the company, versus USD 3.2 million. Diluted Earnings per Share were USD 0.08, up from USD 0.05, and adjusted EBITDA was USD 28.4 million against USD 26.6 million. Adjusted earnings per share guidance was kept at USD 0.75 to USD 0.79, and a new adjusted cash from operations range of USD 84 million to USD 89 million was introduced.

Business Background and Segments

Bioventus, based in Durham, North Carolina, sells products for active healing. Pain Treatments sales were USD 71.3 million, up 6.2%. Surgical Solutions sales were USD 50.5 million, up 0.7%, and Restorative Therapies sales were USD 20.6 million, down 3.4%.

U.S. sales were USD 124.6 million, up 1.0%, while International sales were USD 17.8 million, up 16.4%. Nine-month Net Income attributable to the company was USD 42.5 million against USD 8.0 million, including a USD 21.0 million income tax benefit.

Balance Sheet, Strategic Review and Risks

Cash and equivalents were USD 30.7 million at September 26, 2026, compared with USD 51.2 million at December 31, 2025. The company made a discretionary term Loan prepayment of USD 15.0 million in the quarter, and quarterly cash from operations was USD 20.7 million.

The company said it continues to review strategic alternatives following an unsolicited Acquisition proposal and other expressions of interest. Review costs were USD 3.6 million. The process may or may not lead to a transaction, and the company noted it could affect customer and employee relationships. Softer Restorative Therapies volumes and slow U.S. growth are further risks.

What to Watch Next

Attention turns to delivery against the lowered sales range in the fourth quarter, any update on the strategic review, Pain Treatments trends and further debt reduction. Share moves after a guidance change can stay volatile for several sessions.